Headquarters: Hyderabad, India
2016 generic sales: $1.837 billion (estimate)
With an estimated $1.837 billion in generic sales during its last fiscal year—as calculated by analysts with life science commercial intelligence firm Evaluate—Aurobindo ranks at No. 12 of the world’s top generics players for 2016. Lately, the company has been building up U.S. capacity and was warned by U.S. authorities for manufacturing shortfalls in India.
The company gets about 55% of its sales from the U.S., 28% from Europe and 17% from other markets, according to its annual report (PDF). As of last March, Aurobindo ranked 7th by U.S. prescriptions dispensed, the report states, citing IMS Health data.
Last April, Aurobindo decided to relocate its U.S. headquarters to Durham, North Carolina, and build a manufacturing plant in the city. All told, the $31.7 million investment will create 275 jobs. In New Jersey, the company kicked off construction last August, and announced back in February it’d build a second plant at the site.
More recently, the company got an FDA Form 483 detailing several manufacturing shortfalls at a plant in Hyderabad, India. In a filing with the Bombay Stock Exchange, the company assured investors that the issues had to do with procedural improvements. “None of the observations are related to data integrity," according to the filing (PDF).
The company has 18 manufacturing facilities in India and one in Brazil, according to its report, employing 15,000 employees around the world.
Hyderabad-based Aurobindo filed 22 abbreviated new drug approvals during its 2015-2016 fiscal year, according to the annual report, and received 49 approvals.
Aurobindo's fiscal year ended on March 31, 2017.